Brain Atrophy as an Outcome of Disease-Modifying Therapy for Remitting-Relapsing Multiple Sclerosis

INTRODUCTION: Currently, clinical trials of DMTs strive to determine their effect on neuroinflammation and neurodegeneration. We aimed to determine the impact of currently used DMTs on brain atrophy and disability in RRMS. The main goal of this review is to evaluate the neuroprotective potential of...

Descripción completa

Detalles Bibliográficos
Autores principales: Chylińska, Magdalena, Komendziński, Jakub, Wyszomirski, Adam, Karaszewski, Bartosz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2023
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10484652/
https://www.ncbi.nlm.nih.gov/pubmed/37693228
http://dx.doi.org/10.1155/2023/4130557

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10484652/
https://www.ncbi.nlm.nih.gov/pubmed/37693228
http://dx.doi.org/10.1155/2023/4130557

Ejemplares similares